Intradermal administration of immune modulating Spherical Nucleic Acids as anti-glioma therapy

The treatment of Glioblastoma (GBM) is challenging due to its infiltrative nature, poor drug penetration across the blood-brain barrier and immunosuppressive tumor microenvironment (TME). Standard treatment of surgery, radiotherapy has seen little progress in 15 years, offering a median survival of 15 months. Immune checkpoint inhibitors (ICIs) show promise in many cancers but fail in GBM due to its immune-cold TME. Recent evidence highlights the role of meningeal lymphatic vessels (MLVs) in antigen drainage and immune cell trafficking, making them promising targets for GBM immunotherapy.